Vitamin D3 Metabolites Demonstrate Prognostic Value in <i>EGFR</i>-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance
EGFR tyrosine kinase inhibitors (EGFR TKIs) are the standard of care treatment for patients with <i>EGFR</i>-mutant lung adenocarcinoma (LUAD). Although initially effective, EGFR TKIs are not curative. Disease inevitably relapses due to acquired drug resistance. We hypothesized that vita...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/675 |